KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, a specific tyrosine kinase inhibitor that targets the BCR‐ABL, KIT and PDGFR receptors, is used to treat various cancers, including but not limited to chronic myeloid leukaemia and gastrointestinal stromal tumours.44